Grant: Banting Postdoctoral Fellowship Program
University of Calgary
$140,000.00
Development of an antigen-specific nanomedicine for the treatment of primary biliary cirrhosis, a severe autoimmune disease of the liver
EF 2013-14
Résumé
This proposal is founded on the discovery of a new paradigm in the treatment of autoimmune diseases (caused by the white blood cells of the immune system) of groundbreaking significance. Traditionally, vaccines have been used to expand white blood cells capable of affording protection against viruses, bacteria or cancer, or to delete white blood cells capable of causing autoimmune diseases (such as diabetes). We have developed a 'vaccine' that can cure diabetes by selectively expanding what we call 'autoregulatory' white blood cells, whose function is to put the brakes on the diabetes-causing autoimmune attack. Our vaccine can expand this population of white blood cells, enhancing their diabetes-countering effects. This vaccine can restore normal blood sugar levels in diabetic mice without causing generalized suppression of the immune system.
This anti-autoimmune vaccine platform is based on tiny particles of a metal (many times smaller than a cell; also referred to as nanoparticles -NP-) coated with antigenic targets of beta cell-killer white blood cells (pMHC-coated NPs).
The objective of this proposal is to test the hypothesis that this therapeutic platform can be harnessed for the treatment of other autoimmune diseases. This will be done by focusing on a rare but very serious autoimmune disease of the liver (primary biliary cirrhosis) that is driven by a very specific autoimmune response (against one major protein) and for which there is type of mouse that spontaneously develops this disease. The rarity, severity and immunological properties of this disorder, coupled to the availability of an animal model, afford unique advantages for future drug development, testing and eventual clinical translation of this therapeutic platform.
This work will be done in the context of an interdisciplinary team of established scientists and trainees spanning the spectrum of nanotechnology, biochemistry, immunology and autoimmune disease.
Programme
Banting Postdoctoral Fellowship Program
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
297029
Name
Sokke Umeshappa Channakeshava
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Banting Postdoctoral Fellowships Program
Projecttitle
Development of an antigen-specific nanomedicine for the treatment of primary biliary cirrhosis, a severe autoimmune disease of the liver
Programtype2
Fellowship Programs
Orgnameinp2
University of Calgary
Cihramount2
$140,000
Cihrequipment2
$0
Programname2
Banting Postdoctoral Fellowship Program
Keyworddelim
Autoimmune Disease; Autoreactive T-Cells; Disease-Specific Immunosuppression; Liver Autoimmunity; Nanoparticles; Nanotechnology; New Therapy; Peptide-Major Histocompatibility Complexes; Primary Biliary Cirrhosis; Regulatory T-Cells
Abstract
This proposal is founded on the discovery of a new paradigm in the treatment of autoimmune diseases (caused by the white blood cells of the immune system) of groundbreaking significance. Traditionally, vaccines have been used to expand white blood cells capable of affording protection against viruses, bacteria or cancer, or to delete white blood cells capable of causing autoimmune diseases (such as diabetes). We have developed a 'vaccine' that can cure diabetes by selectively expanding what we call 'autoregulatory' white blood cells, whose function is to put the brakes on the diabetes-causing autoimmune attack. Our vaccine can expand this population of white blood cells, enhancing their diabetes-countering effects. This vaccine can restore normal blood sugar levels in diabetic mice without causing generalized suppression of the immune system.
This anti-autoimmune vaccine platform is based on tiny particles of a metal (many times smaller than a cell; also referred to as nanoparticles -NP-) coated with antigenic targets of beta cell-killer white blood cells (pMHC-coated NPs).
The objective of this proposal is to test the hypothesis that this therapeutic platform can be harnessed for the treatment of other autoimmune diseases. This will be done by focusing on a rare but very serious autoimmune disease of the liver (primary biliary cirrhosis) that is driven by a very specific autoimmune response (against one major protein) and for which there is type of mouse that spontaneously develops this disease. The rarity, severity and immunological properties of this disorder, coupled to the availability of an animal model, afford unique advantages for future drug development, testing and eventual clinical translation of this therapeutic platform.
This work will be done in the context of an interdisciplinary team of established scientists and trainees spanning the spectrum of nanotechnology, biochemistry, immunology and autoimmune disease.
Competitiondate
201310
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Sokke Umeshappa, Channakeshava
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $140,000~ $0~